Source: European Parliament
Question for written answer E-002294/2025
to the Commission
Rule 144
Hilde Vautmans (Renew)
The availability of human plasma is essential for the treatment of thousands of European patients suffering from rare or chronic diseases. At present, however, the EU is highly dependent on plasma imports from countries outside Europe, notably the United States. This dependence poses a strategic risk, especially in light of increasing global demand and geopolitical uncertainties. During the COVID-19 crisis, this vulnerability became painfully visible when patients in Europe faced shortages.
Some Member States, including Belgium and Denmark, have already demonstrated that a model based on voluntary, unpaid donations is not only effective and scalable, but also ethical, safe and crisis resistant. This model offers a viable alternative to commercial systems and deserves recognition and support from Europe.
- 1.Does the Commission recognise that human plasma is a strategic resource for public health in the EU?
- 2.What steps is the Commission taking to develop a coordinated European strategy to ensure plasma self-sufficiency?
- 3.How will the Commission actively support the model of voluntary, unpaid plasma donations within this strategic framework?
Submitted: 6.6.2025